Showa Denko Kabushiki Kaisha

Showa Denko K.k.

Lion Hamigaki Kabushiki Kaisha

Kyodo Insatsu Kabushiki Kaisha

Shinobu Ito

Eiji Ogata

Masahiro Suzuki

Tsutomu Nozawa

Yohei Kurata

Toshi Tsuzuki

Keisuke Mano

Naoaki Misu

Takami Ooe

Yutaka Oonishi

Nobuaki Ishii

Kotaro Yano

Keiji Kawasaki

Kuniaki Shimbo

Michihiro Takama

Kazuo Sekiguchi

Masahiro Yamada

Koichi Wada

Yasuo Saito

Kenichi Nakanishi

Norihiro Tsujii

Yuji Sakai

Yoshihiko Nakahara

Katsuaki Terada

Nobuhiko Miwa

Toshitaka Sunahara

Hiroshi Ikeno

Koichi Showa Denko KK Central Res Lab Wada

Kotaro Showa Denko KK Central Res Lab Yano

Keiji Showa Denko KK Central Res Lab Kawasaki

Nobuaki Showa Denko KK Central Res Lab Ishii

Kazuo Showa Denko KK Cetrl Res Lab Sekiguchi

Yasuo Showa Denko KK Chichibu Works Saito

An object of the present invention is to provide a composition for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens, containing a stable activity-type provitamin; a method for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens by administering the composition; and a method of employing the composition. A composition for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens, contains L-ascorbic acid-2-phosphate and/or &agr;-tocopheryl phosphate as a stable activity antioxidant provitamin.

Composition for enhancing immunological effects

Agent for preventing and treating skin diseases

L-Ascorbic acid 2-phosphate zinc salt and a salt hydrate thereof having excellent solubility and exhibiting good stability even under weakly acidic conditions. Also disclosed is a process of manufacturing L-ascorbic acid 2-phosphate zinc salt by displacing a cation of a salt of an L-ascorbic acid 2-phosphate other than a zinc salt with a zinc cation. Further disclosed is a composition containing L-ascorbic acid 2-phosphate zinc salt or a salt hydrate thereof as an active ingredient.

L-ascorbic acid 2-phosphate zinc salt and process for manufacturing the same

A preparation for administration to animals, comprising a sparingly soluble L-ascorbic acid-2-phosphoric ester salt having a solubility in water of 10 wt % or less, the solubility being a value obtained by placing 100 g of purified water in a 200 ml-volume beaker, stirring the water while keeping the temperature at 20&deg; C., adding 0.1 g of the L-ascorbic acid-2-phosphoric ester salt every 5 minutes by taking care not to cause gelation, and 30 minutes after the addition of L-ascorbic acid-2-phosphoric ester salt when the undissolved L-ascorbic acid-2-phosphoric ester salt is observed visually in the aqueous solution, determining the amount in weight percentage of L-ascorbic acid-2-phosphoric ester salt added based on water, and a method for feeding animals, using the preparation.

Preparation for administration to animals and feeding method thereof

Cosmetics comprising silica-coated metal oxide powder having a thickness of the silica coating of 0.1 to 100 nm, and a photocatalytic activity as measured by tetralin auto-oxidation method of 6 mmH,O/min or less. Silica-coated metal oxide powder coated with a silica coating having an absorption peak intensity ratio I (I&equals;I,/I,, wherein I,is an absorption peak intensity at 1,150 to 1,250 cm,and I,is an absorption peak intensity at 1,000 to 1,100 cm,) between the infrared absorption spectra in the region of 1,150 to 1,250 cm,and the region of 1,000 to 1,100 cm,of 0.2 or more, and having a refractive index of 1.435 or more.

Cosmetics, silica-coated metal oxide powder and production method therefor

A novel ascorbic acid derivative having both sufficiently improved stability and liposolubility, and facilitated cellular uptake. Also disclosed is a process for producing the derivative and a composition capable of effectively providing the action of vitamin C, for use in medical preparations, agricultural chemicals, animal drugs, foods, feeds or cosmetic preparations. The ascorbic acid derivative is a compound represented by the following formula (1) or a salt thereof: ##STR1## wherein R represents an acyl group having eleven or more carbon atoms and n is 0, 1 or 2.

Ascorbic acid derivative and vitamin C preparation containing the same

Disclosed herein are a highly purified tocopheryl phosphate and/or a salt thereof (tocopheryl phosphates) wherein a P,P'-bistocopheryl hypophosphate and/or a salt thereof (P,P'-bistocopheryl diphoshates) is contained in a proportion of not higher than 3% by weight; a process for producing a highly purified tocopheryl phosphate and/or a salt thereof, which comprises the steps of reacting a tocopherol with an oxyphosphorus trihalide followed by treating with an acid or basic aqueous solution to thereby form tocopheryl phosphates (i) in which P,P'-bistocopheryl diphoshates (ii) formed as by-products are contained, hydrolyzing the P,P'-bistocopheryl diphoshates (ii) under acid condition, and, optionally, rendering the hydrolyzate neutral or basic under basic condition; and a method of analyzing tocopheryl phosphates, comprising analyzing a sample containing components (i) and (ii) with the use of a high-performance liquid chromatograph column packed with a gel of a polymethacrylate having, bonded thereto, long-chain alkyl groups. None or only an extremely minute amount of P,P'-bistocopheryl diphoshates are contained in the highly purified tocopheryl phosphates, so that the highly purified tocopheryl phosphates exhibit antioxidant and blood circulation promoting effects, have excellent water solubility, are powdery so that the handling thereof is extremely easy, are free from cutaneous irritation and allergenecity and ensure dermal safety. Therefore, the highly purified tocopheryl phosphates are useful as cosmetic ingredients. The amounts of components (i) and (ii) can be simply measured with high accuracy by the above method.

Highly purified tocopheryl phosphate, process for producing the same,

A vitamin E source composition for administration to animals, which comprises a tocopheryl phosphate, a salt thereof or a composition containing a tocopheryl phosphate or a salt thereof. Also, disclosed is a method of supplying vitamin E to animals which comprises administering to animals the above vitamin E source composition. The tocopheryl phosphoric acid and a salt thereof can be formed into a composition and also can contain an antioxidant or the like.

Method of administering vitamin E to animals and compositions containing

High-  purity tocopherol phosphates, process for the preparation

An anti-stress agent for animals for reducing the growth inhibition or mortality of animals and a method of reducing stress using a feed composition having blended therein the anti-stress agent. The anti-stress agent for animals comprises one or more substances selected from L-ascorbic acid-2-phosphoric acid, a salt thereof and an L-ascorbic acid-2-glucoside, as an active ingredient, for inhibiting the increase of blood plasma lactate dehydrogenase (LDH), malate dehydrogenase (MDH) and aspartate aminotransferase (AspAT) and for inhibiting the increase of stress proteins in blood, which occur when animals are placed under stress. Also disclosed is a feed composition comprising the anti-stress agent, and a method of reducing the stress of animals by supplying the same as feed.

Anti-stress agent for animals and a method of reducing stress in animals

An L-ascorbic acid drug for intracerebral administration comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents. Also disclosed is a method for increasing intracerebral concentration of L-ascorbic acid in a human being comprising administering by injection an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds. Additionally disclosed is a method for increasing intracerebral concentration of L-ascorbic acid in a human being comprising administering by injection an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents. Also disclosed is a method for treating diseases or disorders that result from intracerebral bloodstream inhibition or intracerebral bloodstream lowering comprising administering by injection to a person in need of such treatment, a dosage effective amount of an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds. Additionally disclosed is a method for treating diseases or disorders that result from intracerebral bloodstream inhibition or intracerebral bloodstream lowering comprising administering by injection to a person in need of such treatment, a dosage effective amount of an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents.

Ascorbic acid drugs for intracerebral administration

A side seamless composite type collapsible tube having a tubular nipple section, a shoulder section and a tubular barrel section for receiving an extractable content is provided. The tube sections are formed of a continuous wall of metallic material having a wall thickness from about 20 to 70.mu. with at least a portion of the tubular barrel section coated with a synthetic resinous layer of from about 50 to 500.mu. thick. A method of forming the tube from a metallic blank material is also provided.

Collapsible tube and method of manufacture

Growing community of inventors

Tokyo, Japan

Shinobu Ito